Lycia Therapeutics, Inc. (NASDAQ:LYCA) Sees Significant Growth in Short Interest

Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 304,185 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average trading volume of 400,880 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Lycia Therapeutics to a “hold” rating in a research note on Saturday, October 31st.

Read Our Latest Research Report on Lycia Therapeutics

Lycia Therapeutics Trading Down 5.0%

LYCA stock traded down $1.63 during midday trading on Friday, hitting $31.20. The company had a trading volume of 189,539 shares, compared to its average volume of 471,117. Lycia Therapeutics has a 52 week low of $22.19 and a 52 week high of $36.49.

Insider Buying and Selling at Lycia Therapeutics

In other Lycia Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was bought at an average price of $26.95 per share, with a total value of $223,819.75. Following the purchase, the insider owned 6,858,542 shares of the company’s stock, valued at approximately $184,837,706.90. This trade represents a 0.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have purchased 2,078,749 shares of company stock valued at $38,526,342.

Lycia Therapeutics Company Profile

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Featured Stories

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.